Cornea/External Disease News

Trukera Medical announced the launch of the ScoutPro osmolarity system, the first device unveiled under the company’s new name, according to a press release.

This is a dry eye disease blog. From time immemorial, we have struggled with the out-of-pocket costs of the drugs we prescribe. All of those drugs enjoyed patent protection, allowing the manufacturers to control prices.

Scleritis is inflammation of the sclera and is predominantly autoimmune. Corneal thinning, astigmatism and peripheral ulcerative keratitis are the common corneal changes following scleritis.

MONTEREY, Calif. — OC-01 nasal spray showed a significant decrease in the signs and symptoms of dry eye in patients with autoimmune disease and associated dry eye disease.

AR-15512, a transient receptor potential melastatin 8 agonist, demonstrated significant improvement of dry eye disease signs, symptoms and related quality of life in a phase 2b study.

Timing is everything.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.

Summers mean slowing down. At least, they should. Even if it’s just a little bit.

A phase 3 pivotal study of PL9643, a melanocortin agonist under investigation as a treatment for dry eye disease, demonstrated positive interim results, according to a press release from Palatin Technologies.

Lions Eye Institute for Transplant and Research has entered into an agreement to acquire SightLife, according to a press release.